Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia GravisGlobe Newswire•08/09/2026•11:000 ShareWhiz InsightsGenerateNo content available.
